LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021

By Carolyn Moody, RN - News Editor
Posted on 29 Sep 2021
Print article
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)
Image: LumiQuick Highlights Newly-Launched POC Lateral Flow Assays and ELISA Kits at AACC 2021 (Photo courtesy of LumiQuick Diagnostics, Inc.)

LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) highlighted its newly-launched point-of-care lateral flow assays and ELISA kits at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The event provided an opportunity to connect with global leaders in laboratory medicine, and to discover cutting edge technology and vital research in the field. LumiQuick develops and manufactures extensive product lines that cover point-of-care lateral flow assays, ELISA kits, and other platforms. At AACC 2021, the company highlighted some of its newly-launched products such as the QuickProfile Quantitative Vitamin D rapid test, QuickProfile Zika IgG/IgM antibody rapid test, QuickProfile Chikungunya IgG/IgM antibody rapid test, and Quicknostics Vitamin D ELISA test.

LumiQuick also demonstrated its COVID-19 testing solutions including the QuickProfile 2019-nCoV IgG/IgM Combo Test Card which is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of IgG and IgM antibodies to 2019 novel coronavirus (2019-nCoV, SARS-CoV-2) in human serum, plasma, or whole blood. Rapid 2019-nCoV IgG/IgM Combo Test Card is a supplemental rapid screening tool for symptomatic or asymptomatic carriers of the virus. Also on display was the company’s QuickProfile COVID-19 Antigen Test which is a rapid in vitro immunochromatographic assay for the qualitative detection of SARS-CoV-2 virus antigen present in human nasopharynx.

Related Links:
LumiQuick Diagnostics, Inc. 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more